You are here: Home » News-CM » Companies » News
Business Standard

Lupin launches Testosterone Gel

Capital Market 

Lupin announced the launch of Gel, 1.62% (20.25 mg/1.25 g pump actuation), having received an approval from the (FDA).

Lupin's Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62%.

It is indicated for replacement therapy in males for conditions associated with a or absence of endogenous testosterone:

(congenital or acquired) and (congenital or acquired)

Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had an annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, April 12 2019. 14:22 IST